Overexpression of NIMA-related kinase 2 is associated with progression and poor prognosis of prostate cancer

BMC Urology

Table 2 Association of NEK2 expression with the clinicopathological characteristics of prostate cancer

Clinical feature	IRS of NEK2 in our cohort			NEK2 expression in Taylor dataset
Clinical feature	Case	\( \overline{X}\pm s \)	p	Case	\( \overline{X}\pm s \)	p
Age(years)
<71 years	85	3.67 ± 1.43	0.904	146	7.54 ± 0.29	0.717
≥71 years	95	3.64 ± 1.70	0.904	4	7.48 ± 0.26	0.717
Serum PSA
<4 (ng/ml)	-	-	-	24	7.58 ± 0.32	0.440
≥4 (ng/ml)	-	-	-	123	7.53 ± 0.29	0.440
Gleason score
<8	70	3.81 ± 1.08	<0.001	117	7.48 ± 0.25	0.011
≥8	28	5.36 ± 1.39	<0.001	22	7.71 ± 0.37	0.011
Pathological Stage
T2	70	3.81 ± 1.08	<0.001	86	7.48 ± 0.23	0.063
T3	29	5.31 ± 1.39	<0.001	55	7.58 ± 0.35	0.063
Metastasis
No	99	4.25 ± 1.35	-	122	7.47 ± 0.25	<0.001
Yes	0	-	-	28	7.81 ± 0.33	<0.001
Overall survival
Alive	-	-	-	131	7.51 ± 0.27	0.086
Die	-	-	-	19	7.68 ± 0.38	0.086
PSA failure
Negative	-	-	-	104	7.46 ± 0.25	<0.001
Positive	-	-	-	36	7.66 ± 0.31	<0.001

ISSN: 1471-2490